IAPO launched the Patient-Centred Healthcare Indicators Review
Journal Title: Generics and Biosimilars Initiative Journal - Year 2013, Vol 2, Issue 1
Abstract
In October 2012, the International Alliance of Patients’ Organizations (IAPO) launched its final Patient-Centred Healthcare Indicators Review and accompanying consultation report [1]. The review forms the initial stage of a wider project being undertaken by IAPO to develop a set of process and outcome indicators of patient-centredness. Indicators of patient-centredness relevant to activities, organizations and countries can support the development and implementation of patient-centred policies and be applied by relevant stakeholders to measure the extent and quality of their work towards being patient-centred. The review identifies and assesses current initiatives, which aim to measure the patient-centredness of organizations, countries, activities and any other relevant stakeholders involved in health care. It includes examples from World Health Organization, national health systems, hospitals and others.
Authors and Affiliations
Yasemin Dil
Keywords
Related Articles
- EP ID EP355127
- DOI 10.5639/gabij.2013.0201.005
- Views 128
- Downloads 0
The biosimilar name debate: what’s at stake for public health
As the number of innovator biologics and biosimilars increases worldwide, a growing debate has focused on how these products should be named. The simple concept of a name can have significant impact on prescribing, dispe...
What to look forward to in GaBI Journal, 2012, issue 2
It is my pleasure to introduce the second edition of GaBI Journalwhich contains a number of interesting articles. Professors Benjamin and Kearns present a review of advances in paediatric drug development and labelling,...
Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach
Introduction: Pharmaceutical expenditure continues to rise driven by a number of factors including ageing populations and the continued launch of new premium-priced drugs. Increasing use of generics versus originators an...
Editor’s introduction to the initial issue of the third volume of GaBI Journal
This issue of the GaBI Journal begins with editorial comments from our Deputy Editor-in-Chief Dr Robin Thorpe concerning the Review Article by Azevedo et al. covering biosimilar regulations and their implementation in so...
The authorization of non-biological complex drugs (NBCDs) follow-on versions: specific regulatory and interchangeability rules ahead?
Introduction: Besides biologicals, a new class of complex drugs – non-biological complex drugs (NBCDs), e.g. liposomes, iron carbohydrate products and glatiramoids – has emerged. Originator NBCD products have been approv...